

CASE STUDY – MedTech Funding Mandate (MTFM)

XprESS ENT dilation device

NICE recommends [XprESS](#) ENT dilation device for treating uncomplicated chronic sinusitis in patients who do not have severe nasal polyposis, after medical treatment has failed. It is a minimally invasive alternative to functional endoscopic sinus surgery (FESS), offering equivalent efficacy.

XprESS is currently part of the MTFM. The aim of the MTFM policy is to accelerate equitable patient access to medical technologies that are:

- clinically effective,
- cost saving in three years and
- affordable to the NHS.

The XprESS procedure is carried out under local anaesthetic so there is a reduction in risks associated with general anaesthetic and fewer staff resources required. Procedures can be carried out in treatment room settings rather than in a theatre. There are also fewer carbon emissions as there is reduced reliance on general anaesthesia.

Health Innovation East Midlands (HIEM) were the national Health Innovation Network leads for the adoption and spread of XprESS, working with developers Stryker to encourage ENT teams across the country to implement the device into their pathways.

Locally, we worked with the University Hospitals of Northamptonshire and Northamptonshire ICB to evaluate how the new technology could improve their offer to patients.

What we did:

The HIN's role is to support where there is clinical will by assisting with the review of the technology's benefits against the local patient population, help to build business cases and where appropriate broker discussions with commissioning teams at the ICB.

From an initial meeting, we supported a service review, discussing patient cohorts, NICE recommended uses and potential cost savings.

In order to gather potential cost savings, the clinical team needed to gather data on current FESS numbers and then identify a realistic proportion that would be applicable for XprESS. This informed the business case.

Patient benefits of balloon dilation (XprESS) compared to Functional endoscopic sinus surgery (all statistically significant):

Less post-operative pain relief required
(1.0 vs 2.8 days)

Less post-operative bleeding
(13.8% - 32% vs 56%)

Faster recovery time
(1.7 vs 5 days)

Reference 1. Chandra et al, Laryngoscope 126; January 2016

What we did (continued...):

We brought together, Stryker, financial and contracting leads, commissioners and the clinical leads to progress the business case, using the national Product Toolkit and Strykers business case resources.

Our Analytics and Evaluation Service was able to work with NICE's Resource Impact Tool to enable Trust leads to review the department's budget to identify savings that would free up resources to pay for the XprESS devices.

Through regular touchpoints, we all ensured that the business case aligned with and addressed the Trust's and ICB's priorities, risks and vision for ENT services.

In January 2024, a pilot of the new pathway began.

Outcomes:

XprESS was selected as part of the MTFM as it reduces the length of time that patients spend in hospital, it is a less invasive treatment than the standard treatments – so gives a better patient experience - and it is cost saving within three years.

HIEM supported Northampton General Hospital to pilot the device within their services.

Stryker delivered training to the trust and put clinicians in touch with peers across the country who use the device.

A review of the pilot, undertaken by the University of Northamptonshire, included 32 patients, 18 of whom decided to go ahead with the XprESS treatment. All had good outcomes and were discharged with a Patient Initiated Follow Up available if required. You can watch more about this on the webinar link below.

Despite the lead clinician leaving the Trust in June 2024, the Trust is committed to continuing to offer XprESS as a treatment for patients.

Conclusion:

Getting the right people together from the start, ensured people were working towards the same goal and had a shared understanding of what could be achieved.

Despite the business case taking a while to develop – as data was collected and people's priorities flexed – the end result was a thorough review of how XprESS could make a difference to patients and staff.

The pilot showed good outcomes for the patients and will continue to be delivered by the Trust.



Watch a webinar for more details (NHSFutures registration required)

Contact us

Email: healthinnovation-em@nottingham.ac.uk

X: Healthinn_em

Watch Stryker video <https://view.stryker.com/viewer/66aa11581064cfb9708b1c5f>